Dea K - Search Results

1

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Guérin A, et al. Among authors: dea k. Curr Med Res Opin. 2014 Jul;30(7):1345-52. doi: 10.1185/03007995.2014.904281. Epub 2014 Mar 21. Curr Med Res Opin. 2014. PMID: 24640967

2

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.

Guérin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR. Guérin A, et al. Among authors: dea k. Curr Med Res Opin. 2015 Aug;31(8):1587-97. doi: 10.1185/03007995.2015.1057115. Epub 2015 Jun 29. Curr Med Res Opin. 2015. PMID: 26029864

3

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Guérin A, et al. Among authors: dea k. J Med Econ. 2014 Feb;17(2):89-98. doi: 10.3111/13696998.2013.862251. Epub 2013 Nov 26. J Med Econ. 2014. PMID: 24188054 Free article.

4

Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.

Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. Latremouille-Viau D, et al. Among authors: dea k. J Manag Care Spec Pharm. 2017 Feb;23(2):214-224. doi: 10.18553/jmcp.2017.23.2.214. J Manag Care Spec Pharm. 2017. PMID: 28125373 Free PMC article.

5

The economic burden of brain metastasis among lung cancer patients in the United States.

Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR. Guérin A, et al. Among authors: dea k. J Med Econ. 2016;19(5):526-36. doi: 10.3111/13696998.2016.1138962. Epub 2016 Jan 22. J Med Econ. 2016. PMID: 26735844 Free article.

6

Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.

Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. Guérin A, et al. Among authors: dea k. J Med Econ. 2015 Apr;18(4):312-22. doi: 10.3111/13696998.2014.1003644. Epub 2015 Feb 6. J Med Econ. 2015. PMID: 25565443 Free article.

7

Variation in Care for Patients with Irritable Bowel Syndrome in the United States.

Lacy BE, Patel H, Guérin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R. Lacy BE, et al. Among authors: dea k. PLoS One. 2016 Apr 26;11(4):e0154258. doi: 10.1371/journal.pone.0154258. eCollection 2016. PLoS One. 2016. PMID: 27116612 Free PMC article.

8

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.

Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Wu JJ, et al. Among authors: dea k. J Am Acad Dermatol. 2017 Jan;76(1):81-90. doi: 10.1016/j.jaad.2016.07.042. Epub 2016 Oct 26. J Am Acad Dermatol. 2017. PMID: 27894789

9

Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).

Nellesen D, Dea K, Guerin A, Culver KW, Mutebi A, Dalal A. Nellesen D, et al. Among authors: dea k. Am J Manag Care. 2018 Feb;24(2 Spec No.):SP37-SP42. Am J Manag Care. 2018. PMID: 29689141 Free article. Review. No abstract available.

10

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Laliberté F, et al. Among authors: dea k. Menopause. 2018 Nov;25(11):1297-1305. doi: 10.1097/GME.0000000000001232. Menopause. 2018. PMID: 30358726

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters